Crescent Biopharma
CBIO
41 hedge funds and large institutions have $7.56M invested in Crescent Biopharma in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 11 closing their positions.
152% more capital invested
Capital invested by funds: $3M → $7.56M (+$4.55M)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
19.48% more ownership
Funds ownership: 27.59% → 47.07% (+19%)
14% more funds holding
Funds holding: 36 → 41 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.47M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.39M |
| 3 |
VA
VR Adviser
New York
|
+$818K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$385K |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$332K |
| 2 |
Renaissance Technologies
New York
|
-$202K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$97.1K |
| 4 |
Two Sigma Advisers
New York
|
-$42.1K |
| 5 |
HWA
HCR Wealth Advisors
Los Angeles,
California
|
-$16.9K |
CBIO Hedge Fund Activity: Q4 2024 in Review
41 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2024, worth a combined $7.56M — up 152% from $3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CBIO positions and 11 closed out — a net gain of 5 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $1.47M. The largest seller was Siren LLC, exiting entirely with an estimated $332K sold.
- 41 institutional investors held Crescent Biopharma (CBIO) as of Q4 2024, up from 36 in Q3 2024.
- Funds reported $7.56M of Crescent Biopharma stock for Q4 2024, up 152% quarter-over-quarter.
- 16 funds opened new Crescent Biopharma positions in Q4 2024 and 11 closed out, a net change of +5 holders.
- The largest Crescent Biopharma buyer in Q4 2024 was Logos Global Management, an estimated $1.47M added.
- The largest Crescent Biopharma seller in Q4 2024 was Siren LLC, an estimated $332K sold.
Based on aggregated 13F filings for Q4 2024.